Effect of CPT-11 in combination with other anticancer agents in lung cancer cells

Xin Hai Pei, Yoichi Nakanishi, Koichi Takayama, Feng Bai, Masayuki Kawasaki, Nobuko Tsuruta, Keiko Mizuno, Nobuyuki Hara

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

To determine the optimal combination of commonly used anticancer agents with 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4(1-piperidino)1-piperidino] carbonyloxy camptothecin (CPT-11), for chemotherapy of lung cancer, we studied the effects of SN-38 in combination with six representative anticancer agents on the human small cell lung cancer (SCLC) cell line, NCl N417, and the non-small cell lung cancer (NSCLC) cell line, PC-9. The anticancer activity was evaluated by MTT assay and the effects of drug combinations on ID50 were analyzed by an improved isobologram method. In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol). An additive effect was observed for its combination with bleomycin. Sub-additive and protective effects were found in combination with adriamycin (ADR) and 5-fluorouracil (5-FU). In the NSCLC cell line, supra-additive and marginal supra-additive effects were found for SN-38 in combination with VP-16, ADR, 5-FU and bleomycin. The others showed additive effects with SN-38. No drug showed sub-additive and protective effects with SN-38. These results suggest that all the drugs we selected can be used with SN-38 simultaneously for NSCLC, while for SCLC, cisplatin, VP-16 and Taxol are the most suitable for combination with SN-38.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalAnti-cancer drugs
Volume8
Issue number3
DOIs
Publication statusPublished - Apr 23 1997

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Effect of CPT-11 in combination with other anticancer agents in lung cancer cells'. Together they form a unique fingerprint.

  • Cite this

    Pei, X. H., Nakanishi, Y., Takayama, K., Bai, F., Kawasaki, M., Tsuruta, N., Mizuno, K., & Hara, N. (1997). Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-cancer drugs, 8(3), 231-237. https://doi.org/10.1097/00001813-199703000-00003